

INVESTOR RELATIONS

MetrioPharm Investor Relations News QII 2020

14th Annual General Meeting of MetrioPharm AG

On June 23rd, 2020, the 14th Annual General Meeting of MetrioPharm AG took place without physical participation of the shareholders in accordance with the Covid-19 Ordinance 2, issued by the Federal Council, and with the legal representation of all necessary entities.

After approval of the annual report and the financial statements for 2019, the Board of Directors was discharged and Mr. Christoph von Moos was elected to the Board of Directors for a period of three years. Mr. von Moos is a consultant at Bank Vontobel and has many years of investment and advisory experience. Ferax Treuhand AG was again elected as the auditorial entity.

Of the total share capital of CHF 24'704'000, divided into 123'520'000 registered shares with a par value of CHF 0.20 each, 74'670'181 shares were represented. This corresponds to 60.45 % of the issued shares. The voting results for the 14th Annual General Meeting can be found in detail on our website under MetrioPharm AG: [Voting Results](#).

We would like to take this opportunity to thank all shareholders for their cooperation. Without your commitment the proceedings would not have gone so smoothly. We hope that we will be able to welcome you all personally again next year, to the Annual General Meeting of 2021.

MetrioPharm AG Company Calendar in QII 2020

Due to the ongoing Covid-19 pandemic and the resulting cancellations of previous events and conferences and the general uncertainty that still prevails regarding the coming weeks, our corporate calendar will remain empty for the time being. As soon as this situation changes, we will publish corresponding events on our website at www.metriopharm.com.

Your contact:



Eva Brysch
Head of Investor Relations & Corporate Communications
Tel.: +49-(0)30-3384-395-40
E-Mail: invest@metriopharm.com